Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.
By K. Bushby, R. Finkel, D. Birnkrant, L. Case, P. Clemens, Linda Cripe, A. Kaul, K. Kinnett, C. McDonald, S. Pandya and 4 more. Lancet Neurology, 2010
1,896 citations recorded by the source corpus.
Subfields: Biomedical Engineering, Cellular and Molecular Neuroscience, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/a179d5cdd9823843ac339793bee34c1802805ce1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Cellular and Molecular Neuroscience
In Molecular Biology
Citations in the corpus
- Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018, background): “Duchenne muscular dystrophy (DMD) is an inherited X-linked disease caused by the mutations in the genomic sequence encoding dystrophin, a protein crucial for stabilization of muscle sarcolemma and signaling [109].”
- Evidence‐based path to newborn screening for duchenne muscular dystrophy (2012, background): “The current recommendation for initiation of corticosteroids is to start treatment when boys with DMD have stopped gaining motor skills and not to wait until motor skills have begun to decline.(28) Considering the mean age of DMD diagnosis to be 5 years of age,(29) and that loss of function can begi”
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management (2018, background): “6 Eight of the topics were addressed in the original care considerations: (1) diagnosis, (2) neuromuscular management, (3) rehabilitation management, (4) gastrointestinal and nutritional management, (5) respiratory management, (6) cardiac management, (7) orthopaedic and surgical management, and (8) ”